Navigation Links
Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
Date:3/21/2011

they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: www.shire.com.

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company's Specialty Pharmaceutical and Human Genetic Therapies products, as well as the ability to secure and integrate new products for commercialization and/or development; government regulation of the Company's products; the Company's ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company's products; the Company's ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company's ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the Company's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
2. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
3. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
4. Reportlinker Adds Shire plc: PharmaVitae Profile
5. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
6. Shire plc - Statement re ProAmatine
7. Shire Proposes to Expand Specialist Gastrointestinal Portfolio
8. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
9. Shire Receives CHMP Positive Opinion for VPRIV(TM) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union
10. Shire plc Appoints Two New Board Directors
11. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... -- The National Necrotizing Fasciitis Foundation (NNFF) ... doctors at Vanderbilt University Hospital in Nashville, ... Dr. John Crew , director of the ... in Daly City, CA. ... by Dr. Crew, that had previously saved the lives ...
(Date:8/27/2015)... , Aug. 27, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" ... six-month periods ended June 30, 2015. Biorem,s complete second quarter financial ... FINANCIAL HIGHLIGHTS: in ,000,s except earnings per shareThree-months ended , ... 2014 , 2015 , 2014 Revenue , ... , 4,433 Gross profit , 1,656 , ...
(Date:8/27/2015)... -- GlassesOff (OTCBB: GLSO), a visual neuroscience technology ... vision system, announced today a partnership with eight-time All-Star, ... to develop a new mobile app designed for professional ... on-court performance. Vision is the inception of every ... ball or blocking a pass. The critical impact vision speed ...
(Date:8/27/2015)... ... 27, 2015 , ... METTLER TOLEDO's web-based EasyFinder™ ... choices to a manageable shortlist of bench and floor scales and terminals. Specifying ... best with the customer’s industry and application. , Side-by-side product comparisons and ...
Breaking Biology Technology:Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3METTLER TOLEDO Updates Online Scale Selection Tool 2
... Say Biovail seeing tide changing against management - with ... at meeting, secretly met to change rules, TORONTO, ... said that their lawyers will be in court today ... BVF ) Annual General Meeting,was illegally held and ...
... Md., June 25 Martek Biosciences,(Nasdaq: MATK ... of DHA-omega 3 essential for infant brain and ... in the new Pregnium prenatal,supplement from Walmark. Featuring ... at major retailers in the Czech Republic, Slovakia,and ...
... Pharmaceuticals to develop drug candidate for prevention and ... function in kidney transplantation, LONDON, June 25 ... that the U.S. Food and Drug Administration (FDA) ... Drug,application (IND) for an siRNA therapeutic product based ...
Cached Biology Technology:Eastern European Supplement Leader Walmark Launches Prenatal Product Featuring Martek's life'sDHA(TM) 2Eastern European Supplement Leader Walmark Launches Prenatal Product Featuring Martek's life'sDHA(TM) 3FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics' Unique Proprietary Chemistry 2FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics' Unique Proprietary Chemistry 3
(Date:8/5/2015)... , August 5, 2015 ... titled "Facial Recognition Market - Global Industry Analysis, Size, ... global market for facial recognition is forecast to reach ... by increased demand for surveillance systems by civil and ... number of crimes and terrorist activities across the globe ...
(Date:7/31/2015)... , Kina, 31. juli 2015 Den 10. ... afholdt af BGI fra den 22. - 25. oktober i ... Konferencen fejrer sin 10-års fødselsdag i år. Siden starten ... indflydelsesrige årlige møder på ,omik,-feltet, og er en af ... ICG-10 fokuserer på nylige gennembrud og fremskridt ...
(Date:7/31/2015)... Die 10. internationale Konferenz zu Genomik (ICG-10, ... vom 22. bis 25. Oktober 2015 in ... Die Konferenz feiert in diesem Jahr ihr ... ICG weltweit zu einem der einflussreichsten jährlichen Treffen ... dynamischsten, enthusiastischsten und angenehmsten wissenschaftlichen Zusammentreffen. ...
Breaking Biology News(10 mins):Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3
... UC San Diego-led atmospheric chemistry researchers moved closer to ... science when it made the first-ever direct detection of ... by Kerri Pratt, a Ph.D. student of atmospheric chemistry ... Institution of Oceanography as well as the Department of ...
... A research team may have broken the stubborn impasse ... vaccine, by using an approach that bypasses the usual ... technology that produces molecules that block infection, the scientists ... to HIVthe simian immunodeficiency virus, or SIVthat causes AIDS ...
... Transportation Command, SRA International Inc., United States Army CECOM ... 2009 Supply Chain Excellence Awards, announced here today at ... Industries.The Supply Chain Excellence Awards are bestowed annually by ... global not-for-profit organization and owner of the Supply-Chain Operations ...
Cached Biology News:UCSD researchers make first direct observations of biological particles in high-altitude ice clouds 2UCSD researchers make first direct observations of biological particles in high-altitude ice clouds 3Novel vaccine approach offers hope in fight against HIV 2Supply-Chain Council Announces Winners of 2009 Supply Chain Excellence Awards 2Supply-Chain Council Announces Winners of 2009 Supply Chain Excellence Awards 3
... suspension (non-adherent) cells, RNA ture ... or centrifugation to separate cells ... with 96-well GenePlate®. RiboCap™ plates ... sizes and contain the appropriate ...
... The Zero Background/Kan Cloning Kit ... kanamycin resistance for selection in ... utilizes positive selection to eliminate ... all of the reagents you ...
ANTI DEOXY CORTICO...
ANTI L-DOPA...
Biology Products: